Sentences with phrase «of vaccine manufacturers»

It is likely that although philosophies have changed, dog owners will feel more confident in their care options, and revenues of vaccine manufacturers and veterinarians will not be affected.

If canine and feline vaccination advisory panels have established new recommended guidelines, why would a vet choose instead to take the advice of the vaccine manufacturer's product label?

Not exact matches

The position of parents who use such vaccines is not the same as that of the manufacturers: there are differing areas of responsibility.

However (and incredibly), we may be on the verge of a vaccine against nicotine addiction — how cigarette manufacturers feel about that is certainly a matter for speculation... A high carbohydrate lunch will make you sleepy and sluggish.

If I put myself in a similar position, if I knew a vaccine manufacturer like Merck was a big sponsor of any conference, I probably would have major hesitation and would like to think I would not even think about attending.

For example, I recall that the first sentence of that particular site was that vaccine manufacturers don't list the ingredients of their product anywhere.

Filed Under: Tidbits Tagged With: Autism, Barbie Doll, Chinese Doctors, Eli Stone, George Michael, Hallucinations, Hearing Music, Lots Of Money, Loyal Viewer, Merck, Morsel, Network Television Station, New Tv Show, Pharmaceutical Company, Pilot Episode, Premiere Episode, Screwy, Thimerosol, Tivo, Vaccine Manufacturers

Because the flu vaccine is considered optional, some manufacturers continue to make multi-dose vials of flu vaccine with mercury preservative.

But an investigation from the Institute of Animal Health (IAH), which shares the Pirbright site with vaccine manufacturer Merial.

NOAH is a member of HealthforAnimals, an organisation representing manufacturers of veterinary medicines, vaccines and other animal health products in both developed and developing countries across five continents.

Manufacturer Says Some Lots of H1N1 Lost Potency None of the H1N1 vaccine involved in a voluntary manufacturer's recall due to a loss of potency had been shipped to the Oneida County Health Department, County Executive Anthony J. Picente, Jr. and health department officials confManufacturer Says Some Lots of H1N1 Lost Potency None of the H1N1 vaccine involved in a voluntary manufacturer's recall due to a loss of potency had been shipped to the Oneida County Health Department, County Executive Anthony J. Picente, Jr. and health department officials confmanufacturer's recall due to a loss of potency had been shipped to the Oneida County Health Department, County Executive Anthony J. Picente, Jr. and health department officials confirmed today.

Some Vaccine in Latest Recall Administered by Oneida County Health Department «Potency of Nasal Spray Vaccine in Question — Safety Not an Issue» The Oneida County Health Department's current supply of H1N1 flu vaccine will not be affected by the latest voluntary manufacturer's recall of the product, Daniel W. Gilmore, Acting Director of the departmenVaccine in Latest Recall Administered by Oneida County Health Department «Potency of Nasal Spray Vaccine in Question — Safety Not an Issue» The Oneida County Health Department's current supply of H1N1 flu vaccine will not be affected by the latest voluntary manufacturer's recall of the product, Daniel W. Gilmore, Acting Director of the departmenVaccine in Question — Safety Not an Issue» The Oneida County Health Department's current supply of H1N1 flu vaccine will not be affected by the latest voluntary manufacturer's recall of the product, Daniel W. Gilmore, Acting Director of the departmenvaccine will not be affected by the latest voluntary manufacturer's recall of the product, Daniel W. Gilmore, Acting Director of the department said.

No Recalled Vaccine Shipped to Oneida County Health Manufacturer Says Some Lots of H1N1 Lost Potency None of the H1N1 vaccine involved in a voluntary manufacturer's recall due to a loss of potency had been shipped to the Oneida County Health Department, County Executive Anthony J. Picente, Jr. and health department officials confirmedVaccine Shipped to Oneida County Health Manufacturer Says Some Lots of H1N1 Lost Potency None of the H1N1 vaccine involved in a voluntary manufacturer's recall due to a loss of potency had been shipped to the Oneida County Health Department, County Executive Anthony J. Picente, Jr. and health department officials confManufacturer Says Some Lots of H1N1 Lost Potency None of the H1N1 vaccine involved in a voluntary manufacturer's recall due to a loss of potency had been shipped to the Oneida County Health Department, County Executive Anthony J. Picente, Jr. and health department officials confirmedvaccine involved in a voluntary manufacturer's recall due to a loss of potency had been shipped to the Oneida County Health Department, County Executive Anthony J. Picente, Jr. and health department officials confmanufacturer's recall due to a loss of potency had been shipped to the Oneida County Health Department, County Executive Anthony J. Picente, Jr. and health department officials confirmed today.

The shortage also has become an issue on the campaign trail, with Democratic candidate Sen. John Kerry blaming the Bush administration for not paying attention to warning signs about possible shortages and the Bush campaign inferring that vaccine manufacturers are hindered by fears of lawsuits, something the campaign said Kerry would not move to fix.

The only two manufacturers of human rabies vaccine approved for use in the U.S. have experienced production interruptions and other problems that could result in a shortage, health officials warn.

The manufacturer of the sole dengue vaccine on the market says a new study shows that it should only be used in people who have had a previous infection from the mosquito - borne virus.

Extracting the vaccine would be simple; manufacturers could squeeze the bright green juice from the tobacco leaves, harvest the human viral DNA, and then destroy any remaining traces of the genetically mixed virus.

Then she works with vaccine manufacturers, the World Health Organization, and other stakeholders to try to improve such traits in the next generation of vaccines.

If the legal atmosphere becomes too difficult for vaccine manufacturers, they could stop producing them or be forced out of business.

The journey vaccines take — from the manufacturer to the patient (the supply chain)-- entails enormous obstacles including long and inefficient transportation routes and lack of refrigeration.

One of the Lyon - based investors is vaccine manufacturer Sanofi Pasteur, whose president, Jacques Berger, sees many benefits to the changes: «There's no rivalry between those who want to work in state - funded research and those who want to work in the private sector,» he says.

Phages would require a less traditional approach to get official approval, such as the annual process for influenza vaccines in which manufacturers secure approval of new formulas based on the flu bug that is going around that year, instead of conducting big clinical trials every time.

WHO's Chan holds a teleconference with vaccine manufacturers around the globe to discuss the production of a pandemic vaccine.

At this point, the U.S. government expects manufacturers to deliver 45 million to 52 million doses of the vaccine by mid-October, said Jay Butler, head of the H1N1 task force for the U.S. Centers for Disease Control and Prevention.

They say that opening companies up to lawsuits «could drive vaccine manufacturers from the market and halt the future production and development of childhood vaccines in this country.»

Supporters of the AMC concept say that it addresses an immediate problem by providing a reason for manufacturers to provide pneumococcal vaccines to needy populations.

Unlike other medical treatments for which companies are driven to keep their products safe because of liability threats, their brief says «the Vaccine Program itself provides no incentive to vaccine manufacturers to make their vaccines safer.Vaccine Program itself provides no incentive to vaccine manufacturers to make their vaccines safer.vaccine manufacturers to make their vaccines safer.»

In response, health agencies could then advise manufacturers of flu drugs and vaccines to ramp up production, or could instigate stricter public - health measures to prevent transmission.

It seems unlikely that manufacturers will pre-emptively produce more vaccine on the basis of a potential threat.

The current system was established by the National Childhood Vaccine Injury Act in 1986, when vaccine manufacturers were facing a flood of lawsuits and threatening to pull out of the vaccine - making buVaccine Injury Act in 1986, when vaccine manufacturers were facing a flood of lawsuits and threatening to pull out of the vaccine - making buvaccine manufacturers were facing a flood of lawsuits and threatening to pull out of the vaccine - making buvaccine - making business.

Public health agencies did suggest manufacturers eliminate or reduce the amount of thimerosal in vaccines and many have done so.

Easter may have come and gone, but manufacturers of flu vaccines are always hunting for eggs.

The PneumoADIP anticipates that a few so - called early adopter countries would realistically order one million to three million doses of vaccine in the next three years at a range of (donor - subsidized) prices that manufacturers might accept, observes Angeline Nanni, the group's director of vaccine supply and finance.

Nearly 80 million people in 77 countries received the influenza vaccine with WHO's help — including providing a «seed» strain of the virus used by manufacturers — but the report says that «numerous systemic difficulties» slowed distribution to low - resource countries.

Vaccine manufacturers have notified officials that they can't make good on their targets, Anne Schuchat, director of CDC's National Center for Immunization and Respiratory Diseases, said during a press conference today.

M. - P.K.: They have to sign an agreement that they hold the vaccine manufacturers harmless in case of adverse events.

In a dissenting opinion, they accused the court of imposing «its own bare policy preferences» to protect vaccine manufacturers and said it was important for companies to be pushed, at times by litigation, to improve on existing vaccines.

The case was closely watched on all sides because it challenged the 1986 National Childhood Vaccine Injury Act (NCVIA); that act sought to protect manufacturers from a flood of liability claims — and thereby stabilize the vaccine market — but also preserve a family's right to be compensated for vaccine inVaccine Injury Act (NCVIA); that act sought to protect manufacturers from a flood of liability claims — and thereby stabilize the vaccine market — but also preserve a family's right to be compensated for vaccine invaccine market — but also preserve a family's right to be compensated for vaccine invaccine injuries.

And even if they were more dangerous than common flu strains, it would not make any difference because manufacturers kill the virus as part of the vaccine production process, notes the group.

The study was funded in part by the rotavirus and pneumocccal vaccine manufacturers, and was a part of the evaluation plan of vaccine introduction of the Israel Ministry of Health.

The Lancet and most of the article's coauthors ultimately disowned the study because its lead author had not divulged that he was also being paid to conduct research for parents seeking to sue vaccine manufacturers.

The Streptococcus pneumoniae Genome Diversity Project More information about S. pneumoniae, on a site supported by vaccine manufacturer Wyeth - Lederle List of the more than 45 microbial genomes so far completed, with links to others still in progress

Stockpiles of cholera and yellow fever vaccine are limited, but a new cholera vaccine manufacturer may help ease the shortage.

To reduce the possibility of such side effects, the manufacturer of the new vaccines launched separate clinical trials, each one including some 60,000

He is now consultant to vaccine manufacturers, biotechnology companies and non-profit research organizations as principal of Vaxconsult, LLC.

Dr Ho works in NIBSC since 1998 and leads R&D and standardisation projects collaborating with vaccine manufacturers in laboratory evaluation of product characterisation and quality control assays for novel bacterial vaccines, including protein subunit, polysaccharide - protein conjugates, viral vector and live bacterial vaccines.

Moving the Needle provides quarterly updates from PATH's Center for Vaccine Innovation and Access (CVIA) on our vaccine development efforts, as well as related supporting work, such as developing human challenge models, building capacity of developing - country vaccine manufacturers, and evaluating new adjuvants and other novel vaccine technoVaccine Innovation and Access (CVIA) on our vaccine development efforts, as well as related supporting work, such as developing human challenge models, building capacity of developing - country vaccine manufacturers, and evaluating new adjuvants and other novel vaccine technovaccine development efforts, as well as related supporting work, such as developing human challenge models, building capacity of developing - country vaccine manufacturers, and evaluating new adjuvants and other novel vaccine technovaccine manufacturers, and evaluating new adjuvants and other novel vaccine technovaccine technologies.

One application of sieve analysis, once it's learned that a vaccine's efficacy depends on the genetics of the pathogen, is for the vaccine manufacturer to add a different strain or strains to the vaccine to increase its protectiveness.

Sanjay Gurunathan from Sanofi Pasteur, manufacturer of one of the vaccines used in RV144, said a new partnership of the US National Institute of Allergy and Infectious Diseases, The Bill & Melinda Gates Foundation, HIV Vaccine Trials Network, US Military HIV Research Program (MHRP), and Sanofi Pasteur — known as the Pox Protein Public Private Partnership, or P5 — will aim to increase vaccine efficacy from the 31.2 percent of the RV144 trial to 50 pVaccine Trials Network, US Military HIV Research Program (MHRP), and Sanofi Pasteur — known as the Pox Protein Public Private Partnership, or P5 — will aim to increase vaccine efficacy from the 31.2 percent of the RV144 trial to 50 pvaccine efficacy from the 31.2 percent of the RV144 trial to 50 percent.

Dr. Jadhav is associated with Developing Countries Vaccine Manufacturers» Network (DCVMN) since its inception in 2000 and was the President of DCVMN from 2003 till 2008.